Chris O'Donnell

Chris O'Donnell has extensive experience in the biopharmaceutical industry, currently serving as a Member of the Board of Directors at Arrakis Therapeutics and holding a long tenure at Pfizer since July 1999, where roles include Vice President of Business Development and Partner at Pfizer Ventures. O'Donnell has spearheaded efforts in early-stage biotechnology investments and led various medicinal chemistry initiatives across oncology and neuroscience, contributing to multiple clinical candidates. O'Donnell's Board and advisory roles with several biotechnology firms reflect a commitment to advancing therapeutic innovations in multiple disease areas. O'Donnell holds a Postdoctoral degree and a PhD in Organic Chemistry from UC Irvine and University of Wisconsin-Madison, respectively, along with a Bachelor's degree from the University of Illinois Urbana-Champaign.